In the BioHarmony Drug Report Database

"Preview" Icon

Fostamatinib

Tavalisse, Tavlesse (fostamatinib) is a small molecule pharmaceutical. Fostamatinib was first approved as Tavalisse on 2018-04-17. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. Tavalisse’s patent is valid until 2032-07-27 (FDA).

 

Trade Name

 

Tavlesse
 

Common Name

 

fostamatinib
 

ChEMBL ID

 

CHEMBL2103830
 

Indication

 

thrombocytopenia
 

Drug Class

 

Tyrosine kinase inhibitors; phosphoro-derivatives

Image (chem structure or protein)

Fostamatinib structure rendering